



**International Myeloma Foundation (IMF) and Pfizer Inc.
Independent Medical Education**

**Addressing Multiple Myeloma Gaps in Care
for Patients in Latin America
A Visiting Professorship Program**

Request for Proposals (RFP)

I. Background

About International Myeloma Foundation

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest global organization focusing specifically on multiple myeloma. The IMF's reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure through our four pillars: Research, Education, Support, and Advocacy. Click here to know more about IMF: [Multiple Myeloma Information | International Myeloma Foundation](#)

About Pfizer Global Medical Grants & Partnerships

Pfizer Global Medical Grants & Partnerships (GMGP) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMGP competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an Expert Review Panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved

in any aspect of project development, nor the conduct of the independent education program.

About the Visiting Professorship (VP) Program

The intent of this RFP is to provide financial support to organizations to host and coordinate a medical education program at their organization, to be led by two international Visiting Professors with expertise matched to the organization's unmet educational needs surrounding the management of **Multiple Myeloma**.

Healthcare practitioners, researchers and patients will benefit from the knowledge and on-site presence of distinguished medical experts who might otherwise be inaccessible.

The goals of this program are to provide meaningful practice-based educational experiences for oncology-care teams in Latin America, building capacity in Latin American cancer medicine by identifying gaps in patient care and assisting with solutions, and building global collaborations between Latin American and Western Multiple Myeloma care professionals.

II. Eligibility

Geographic Scope:	Argentina, Brazil, Colombia and Mexico.
Applicant Eligibility Criteria	<ul style="list-style-type: none"> • Applicant (Principal Investigator; PI) must have a medical degree (MD, MBBS, or equivalent), and hold a position as Hematologist managing patients with Multiple Myeloma in the respective market. • Principal Investigator should serve as Chair of the proposed VP two-day medical education program. • Applicants must be from healthcare/medical organizations that provide comprehensive medical care for patients with Multiple Myeloma, located in Argentina, Brazil, Colombia, or Mexico. • The institution and medical hosting team must be based in one of the countries listed above. • Only institutions / organizations / associations are eligible to receive Grants, not individuals or physician-owned medical practice groups. • Institutions applying for this grant must have proven hematology-care capacity to host this Visiting Professorship. • The project can involve multiple departments within an institution and/or between different institutions / organizations / associations. In this case all institutions must have a relevant role and the requesting organization must have a key role in the project. • The project/program lead must be an employee or independent contractor of the requesting organization. • Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants approved to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.

III. Requirements

Date RFP Issued:	November 14, 2024
Clinical Area:	Oncology - Hematologic - Multiple Myeloma
Area of Interest for this RFP:	<p>The intent of this Visiting Professor program is to improve patient care for Multiple Myeloma patients in Latin America by sharing advanced medical expertise, build capacity in Latin American cancer medicine by identifying unresolved gaps in patient care, and bringing solutions and building global collaborations between Latin American and Western Multiple Myeloma care professionals.</p> <p>Application proposals from Organizations interested in hosting this program must include but not limited to the following information:</p> <ul style="list-style-type: none"> ● Description of Organization’s mission, vision, impact, and reach. This includes statistics and descriptions of the following: <ul style="list-style-type: none"> ● Mission and Vision. ● Numbers of hospitals and clinics in organization; regional reach and coverage. ● Numbers of patients served and patient visits. ● Numbers of hospital staff, including all employees, clinical faculty, registered nurses, medical residents and fellows, medical students, and academic faculty and students. ● Prevention, screening, diagnosis, and treatment services, certifications and specialties. ● Clinical trials experience ● Educational platforms and programs. ● Any innovation or research breakthroughs. ● Description of the Organization’s care gaps, unmet needs, challenges, and questions surrounding the management of patients with Multiple Myeloma, for which a Visiting Professor could provide education or support. Relevant clinical information for the development of the program may include but is not limited to: <ul style="list-style-type: none"> ● Training needs of the healthcare team including physicians, nurses, and other allied health professionals. ● Cancer care disparities that can be impacted with this program. ● MM diagnosis and referral to appropriate specialist ● Treatment landscape and emerging therapies (e.g. CAR-Ts, Bispecific antibodies, immunotherapies and other novel agents) ● Therapy management and patient monitoring ● Agenda for a two-day medical education program that should include but is not limited to: <ul style="list-style-type: none"> ● Example agenda for meetings during two-day program including a combination of lectures, patient case reviews, informal discussions, and other meaningful interactions with the local

	<p>care team that would be facilitated. This Program is expected to be held in English due to the International Visiting Professors but can have simultaneous translation to Spanish or Portuguese if needed (costs can be reflected in the operational budget).</p> <ul style="list-style-type: none"> • Expected number of health care professionals attending this Program (e.g., own site physicians, invitees from satellite hematology sites or allied healthcare institutions, etc.) • Expected local leaders, faculty, speakers, etc. <ul style="list-style-type: none"> • Budget template for all <u>local</u> costs that can include, meeting rooms, AV, local onsite management, local faculty fees, onsite logistics, planning and staffing, simultaneous translation, not to exceed \$30,000 USD. Travel expenses and honoraria for the Visiting Professors will be covered separately by the IMF/Pfizer collaboration <u>and should not be included in the budget.</u> • Expected / desired results and outline of 12-month outcome metrics for Visiting Professorship Program that will report on enduring changes that have occurred in improvements in patient care and physician education/knowledge. A 30-day report on activities and outcomes that occurred during the Visiting Professorship Program will also be required. This report can include but is not limited to details on: <ul style="list-style-type: none"> • Impact on patient management and outcomes • Impact on physician education and knowledge • Sustainability of practice changes • Potential replicability and dissemination • Collaborations with other oncology sites, medical societies, academia, etc. • Publications and/or communications plan
<p>Target Audience:</p>	<p>Medical <u>hematologists</u> should serve as Principal Investigator (PI) and Program Chair, but all other medical disciplines can be included in the Program plan, such as: <u>nurses, pharmacists,</u> allied Multiple Myeloma healthcare providers, and <u>infectiology, orthopedic, emergency and intensive care,</u> pathology and nuclear medicine MDs.</p>
<p>Expected Approximate Monetary Range of Grant Applications:</p>	<ul style="list-style-type: none"> • Individual Grant amounts will be up to \$ 30.000 to cover for local costs related to this program. • Please note: IMF will create a multidisciplinary team of potential Visiting Professors to fulfill the objectives of each selected program. • Approximately five sites will be supported by this educational program. • Applications will be reviewed by an expert review panel (ERP)

	<ul style="list-style-type: none"> The amount of the award will depend upon the expert review panel's evaluation of the proposal and costs involved and will be stated clearly in the award agreement.
Key Dates:	<ul style="list-style-type: none"> RFP release date: November 14, 2024 Grant Application due date: January 19, 2025. Please note the deadline is 23:59 Eastern Time (New York, GMT -5). Review of applications by ERP: March 2025 Anticipated Grant Award Notification Date: April 2025 Grants will be distributed following a fully executed agreement. Anticipated Project Start Dates: on or after June 1, 2025
How to Apply:	<p>Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.</p> <ul style="list-style-type: none"> Please go to https://www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click "Create your password". <i>[Note: there are individual portals for each grant application type. Please be sure to use the URL above.]</i> In the application: <ul style="list-style-type: none"> For the question "What type of request are you submitting?" select "Support for a Visiting Professorship". For the question "Are you replying to a Request for Proposal as part of the Competitive Grant Program?" select Yes. Select the following Competitive Grant Program Name: 2024 ONC LATAM Addressing Multiple Myeloma Gaps in Care for Patients IME. Select the following Primary Area of Interest: Oncology - Hematologic - KG; Select Hematologic - Multiple Myeloma for the Cancer Type Detail question. Requirements for submission: <ul style="list-style-type: none"> Complete all required sections of the online application and upload your project proposal in the Proposal/Protocol field. If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page. <p>IMPORTANT: Be advised applications submitted after the due date will not be reviewed.</p>
Questions:	<p>If you have questions regarding this RFP, please direct them in writing to Miguel Briceno (Miguelangel.briceno@pfizer.com) with the subject line: 2024 ONC LATAM Addressing Multiple Myeloma Gaps in Care for Patients IME.</p>

<p>Grant Agreements:</p>	<ul style="list-style-type: none"> • If your Grant application is approved, your Institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement. • Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety. • Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application. • Except where prohibited by applicable local laws or regulations and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization in its country of domicile. • This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.
<p>Review and Approval Process:</p>	<ul style="list-style-type: none"> • Grant requests received in response to a specific RFP are reviewed by an expert review panel (ERP) to make final grant decisions. • The panels are comprised of professionals from the medical community with advanced degrees and expertise in particular clinical areas, or specific needs of a geographic region/learner group, or expertise in research, continuing professional development or quality improvement.
<p>Mechanism by which Applicants will be Notified:</p>	<ul style="list-style-type: none"> • All applicants will be notified via email by the dates noted above. • Applicants may be asked for additional clarification during the review period.